Pituitary & hypothalamus

Long-term outcomes in patients with Cushing's disease vs nonfunctioning pituitary adenoma after pituitary surgery: an active-comparator cohort study

Eur J EndocrinolPublished Population-based retrospective cohort study

Main finding · Primary composite endpointResult — go to the resultHazard ratio 2.75 95% CI 1.54–4.90

Authors' conclusion

Even after pituitary surgery, CD patients faced a higher hazard of complications, especially psychiatric hospitalizations and sepsis.

Study context

Population
Hospitalized patients undergoing pituitary surgery for Cushing's disease (CD) or nonfunctioning pituitary adenoma (NFPA), Swiss Federal Statistical Office data, January 2012–December 2021propensity score matched
Participants
116 vs 396
Exposure
CD vs NFPA after pituitary surgery
  • CDn = 116
  • NFPAn = 396reference
Outcome
Composite of:
  • All-cause mortality
  • MACE (MI, unstable angina, HF, cardiac arrest, ischemic stroke)
  • Hospitalization for psychiatric disorders
  • Sepsis
  • Severe thromboembolic events
  • Fractures needing hospitalization
Follow-up
Median 50.0 months (IQR 23.5, 82.0)
Methodological details1:5 propensity score matching, active-comparator
  • 1:5 propensity score matching
  • Active-comparator

Main finding

Primary composite endpoint

Hazard ratio

2.75

95% CI 1.54–4.90

By group

CD

40.6 events per 1000 person-years

NFPA

15.7 events per 1000 person-years

CDvs NFPA
HR 2.75 (95% CI 1.54–4.90)

As reported in the abstract

Observational data: associations, not effects.

Secondary outcomes

OutcomeHR (95% CI)
Hospitalization for psychiatric disorders3.27 (1.59–6.71)
SepsisTrend3.15 (.95-10.40)

Original publication

Long-term outcomes in patients with Cushing's disease vs nonfunctioning pituitary adenoma after pituitary surgery: an active-comparator cohort study. Eur J Endocrinol. Published 1 July 2024. doi:10.1093/ejendo/lvae069

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.